Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Ipilimumab vs Placebo in Adjuvant Renal Cell Carcinoma
NCT03138512Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2017
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in renal cell carcinoma (RCC), sponsored by Bristol Myers Squibb. Started Jul 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03138512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138512.